臺灣博碩士論文加值系統

一氧化氮（NO）於發炎及癌化過程中扮演關鍵角色。一氧化氮合成（nitric oxide synthase，NOS）具有三種異構型態 (isoform )，分別是內皮性NOS（endothelial NOS，eNOS），神經性NOS（neuronal NOS，nNOS），及誘發性NOS（inducible NOS，iNOS）。目前許多關於癌症的研究都將焦點集中在iNOS上，而iNOS與口腔癌之研究仍然未被詳細探討。故本論文之研究目的是探討人類口腔癌前期與上皮癌病灶，及以DMBA誘發倉鼠頰囊袋黏膜癌化過程中誘發性一氧化氮合成（iNOS）的免疫組織化學及細胞中mRNA的角色扮演。動物實驗方面，將33隻雄性年輕成年倉鼠（Syrian golden hamsters）以隨機方式分成三大組：13隻以0.5 % DMBA塗抹為實驗組，10隻以礦物油塗抹為對照組，及10隻不做任何處理（對照組）。人體檢體方面所收集之組織病理診斷及樣本數如下：輕微口腔上皮發育異常（mild oral epithelial dysplasia，mild OED）10例，中度（moderate）及嚴重（severe）口腔上皮發育異常10例；黏膜下纖維化（submucous fibrosis）10例；疣狀增生（verrucous hyperplasia）10例；疣狀上皮癌（verrucous carcinoma）10例；分化良好（well-differentiated）鱗狀上皮細胞癌（squamous cell carcinoma，SCC）10例，中度分化（moderate-differentiated SCC）及分化不全（poor-differentiated）鱗狀上皮細胞癌（SCC）10例；正常口腔黏膜（normal oral mucosa）5例。本研究發現一氧化氮合成在人類癌前期病變及惡性上皮癌病灶與DMBA誘發倉鼠頰囊袋上皮癌均可以見到細胞質及細胞核的染色呈陽性反應。人類正常口腔黏膜與未經處理及以礦物油處理的倉鼠頰囊袋黏膜中沒有誘發性一氧化氮合成的表現。另一方面，於DMBA誘發倉鼠頰囊袋癌病灶與人類口腔癌前期病變及惡性上皮癌病灶均可見到誘發性一氧化氮合成mRNA的表現。而未經處理及以礦物油處理的倉鼠頰囊袋黏膜與人類正常口腔黏膜中誘發性一氧化氮合成mRNA均未表現。這些發現可證實誘發性一氧化氮合成與口腔癌的發生有關聯。

Nitric oxide (NO) plays a key role in the processes of inflammation and carcinogenesis. Three isoforms of nitric oxide synthase (NOS) have been identified: endothelial NOS (eNOS), neuronal NOS (nNOS), and inducible NOS (iNOS). To date, most cancer studies are concerned with iNOS. The role of iNOS in the oral carcinogenesis remains to be elucidated. The purpose of the present study is to investigate the immunohistochemical and mRNA expression of iNOS in human oral premalignant & malignant epithelial lesions and DMBA-induced hamster buccal carcinomas. Thirty-three outbred adult young (six weeks old) male Syrian golden hamsters were randomly divided into three groups: DMBA (0.5%) painted group（n=13）, mineral oil-treated group（n=10）, and untreated group（n=10）. Surgical human oral specimens with the following histological diagnoses were collected: mild (n=10), moderate and severe (n=10) dysplasia; submucous fibrosis (n=10); verrucous hyperplasia (n=10), verrucous carcinoma (n=10); squamous cell carcinoma (well-differentiated, n=10; moderate-differentiated and poor-differentiated, n=10); normal oral mucosa (n=5). Cytoplasmic and nuclear stainings were observed in both human oral premalignant & malignant epithelial lesions and DMBA-induced hamster buccal carcinomas. Inducible NOS staining was not demonstrated in the human normal oral mucosa, in the untreated or mineral-oil treated hamster pouches. On the other hand, iNOS mRNA expression was demonstrated in all the DMBA-induced carcinomas as well as in the majority of human oral premalignant and malignant epithelial lesions. No iNOS mRNA was detected in the untreated, mineral-oil treated pouches and the human normal oral mucosa. These findings suggested that iNOS may play an important role in the oral carcinogenesis.

壹、摘要
中文摘要
英文摘要
貳、緒論
參、文獻回顧
肆、材料與方法
伍、結果
陸、討論
柒、圖表
捌、參考文獻

1.Saiki, R. et al.（1985）Enzymatic amplification of beta-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anemia. Science 230, 1350.
2.Saiki, R.K. et al.（1988）Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239, 487.
3.Scharf, S. et al.（1986）. Science. 230, 1076.
4.Eckert, K.A. and Kunkel, T.A.（1990）High fidelity DNA synthesis by the Thermus aquaticus DNA polymerase. Nucl. Acids Res. 18, 3739.
5.Powell, L.M. et al.（1987）. Cell. 50, 831-840.
6.Bredt, D.S., Hwang, P.M. and Snyder, S.H.（1990）Nature 347, 768-770.
7.Billar TR. Nitric oxide. Novel biology with clinical relevance. Ann Surg 1995；221：339-349.
8.Nathan, C.F., and Hibbs, J.B., Jr. （1991）. Curr. Opin. Immunol. 3, 65-70.
9.Lowenstein, C.J. and Snyder, S.H. （1992）Cell 70, 705-707.
10.Lowenstein CJ, Kinerman JL, Snyder SH. Nitric oxide：a physiologic messenger. Ann Intern Med 1994；120：227-237.
11.Knowles RG, Moncada S. Nitric oxide synthases in mammals. Biochem J 1994；298：249-258.
12.Yui, Y., Hattori, R., Kosuga, K., Eizawa, H., Hiki, K. and Kawai, C.（1991）J. Biol. Chem. 226, 12544-12547.
13.Xie, Q., Cho, H.J., Calaycay, J., Mumford, R.A., Swiderek, K. M., Lee, T. D., Ding, A., Troso, T. and Nathan, C. 1992 Science 256, 225-228.
14.Lyons, C. R., Orloff, G. J. and Cunningham, J. M.（1992）J. Biol. Chem. 267, 6370-6374.
15.Lowenstein, C. J., Glatt, C. S., Bredt, D. S. and Snyder, S. H.（1992）Proc. Natl. Acad. Sci. USA 89, 6711-6715.
16.Wood, E. R., Berger, H., Sherman, P.A. and Lapetina, E.G.（1993）Biochem. Biophys. Res. Commun. 191, 767-774.
17.Nathan, C.（1992）FASEB J. 6, 3051-3064.
18.Sherman, P. A., Laubach, V. E., Reep, B. R. and Wood. E. R.（1993）Biochemistry 32, 11600-11605.
19.Bred, D.S., Hwang, P.M., Glatt, C. E., Lowenstein, C., Reed, R.R. and Snyeer, S.H.（1991）Nature 351, 741-718.
20.Nakane, M., Schmidt, H. H. H. W., Pollock, J.S., Forstermann, U. and Murad, F.（1992）FEBS Lett. 316, 175-180.
21.Sessa, W. C., Harrison, J. K., Barber, C. M., Zeng, D., Durieux, M. E., D’Angelo, D. D., Lynch, K. R. and Peach, M. J.（1992）J. Biol. Chem. 267, 15274-15276.
22.Lamas, S., Marsden, P.A., Li, G. K., Tempst, P. and Michel, T.（1992）Proc. Natl. Acad. Sci. USA 89, 6348-6352.
23.Jaussens, S. P., Shimouchi, A., Quertermous, T., Bloch, D. B. and Bloch, K.D. （1992）J. Biol. Chem. 267, 14519-14522.
24.Nathan C, Xie QW. Nitric oxide synthases：roles, tolls, and controls. Cell 1994；78：915-919.
25.Tamir S, Tannenbaum SR. The role of nitric oxide in the carcinogenic process. Biochem Biophys Acta 1996；1228：F31-F36.
26.Calmels S, Hainaut P, Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 1997；16：3365-3369.
27.Nguyen T, Brunson D, Crespi CL, et al. DNA damage and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992；89：3030-3034.
28.Chhatwal VJ, Moochhala SM, Chan ST, et al. Nitric oxide and cancer. Med Hypotheses 1996；46：21-24.
29.Andrade SP, Hart IR, Piper PJ. Inhibitors of nitric oxide synthase selectively reduce flow in turnout-associated neovasculature. Br J Pharmacol 1992；107：1092-1095.
30.Maeda H, Noguchi Y, Sato K, et al. Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn J Cancer Res 1994；85：331-334.
31.Buttery LDK, Springall DR, Andrade SP, et al. Induction of nitric oxide synthase in the neovasculature of experimental tumors in mice. J Pathol 1993；171：311-319.
32.Lejeune P, Lagadec P, Onier N, et al. Nitric oxide involvement in tumor-induced immunosuppression. J Immunol 1994；152：5077-5083.
33.Nguyen T, Brunson D, Crespi CL, et al. DNA damange and mutation in human cells exposed to nitric oxide in vitro. Proc Natl Acad Sci USA 1992；89：3030-3034.
34.Oshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors：possible role of nitric oxide in carcinogenesis. Mutat Res 1994；305：253-264.
35.Haswell-Elkins MR, Saraug S, Tsuda M, et al. Liver fluke infection and cholangiocarcinoma: model of endogenous nitric oxide and extragastric nitrosation in human carcinogenesis. Mutat Res 1994；305：241-252.
36.Smith CW, Anderson DC. PMN adhesion and extravasation as a paradigm for tumor dissemination. Cancer Metastasis Rev 1991；10：61-78.
37.Radomski MW, Jenkins DC, Holmes L, et al. Human colorectal adenocarcinoma cells: differential nitric oxide synthesis determines their ability to aggregate platelets. Cancer Res 1991；51：6073-6078.
38.Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc Natl Acad Sci USA 1991；88：4651-4655.
39.Vidal MJ, Zocchi MR, Poggi A, et al. Involvement of nitricoxide in tumor cell adhesion to cytokine-activated endothelial cells. J Cardiovasc Pharmacol 1992；20（suppl）：S155-159.
40.Filep JG, Filep EF, Sirois P. Nitric oxide modulates vascular permeability in the rat coronary circulation. Br J Pharmacol 1993；108：323-326.
41.Dong Z, Staroselsky AH, Qi X, et al. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murine melanoma cells. Cancer Res 1994；54：789-793.
42.Yim C, Bastian NR, Smith JC, et al. Macrophage nitric oxide synthesis delays progression of ultraviolet light-induced murine skin cancers. Cancer Res 1993；53：5507-5511.
43.Orlando RC. Esophageal epithelial defense against acid injury. J Clin Gastroenterol 1991；13：S1-5.
44.Rubanyi GM, Ho EH, Canotr EH, et al. Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes. Biochem Biophys Res Commun 1991；181：1392-1397.
45.Wink DA, Hanbauer I, Krishna MC, et al. Nitric oxide protects against cellular damage and cytotoicity from reactive oxygen species. Proc Natl Acad Sci USA 1993；90：9813-9817.
46.Lazlo F, Whittle BJR, Moncada S. Time-dependent enhancement or inhibition of endotoxin-induced vascular injury in rat intestin by nitric oxide synthase inhibitors. Br J Pharmacol 1994；1309-1315.
47.Kroncke KD, Fehsel K, Kolb-Bachofen V. Nitric oxide: cytoxicity verus cytoprotection — how, why, when and where? Nitric oxide: Biology and chemistry 1997；1：107-120.
48.Dimmeler S, Zeiher AM. Nitric oxide and apoptosis: another paradigm for the double-edged role of nitric oxide. Nitric Oxide: Biology and Chemistry 1997；1：275-281.
49.Robertson FM, Long BW, Tober KL, et al. Gene expression and cellular sources of inducible nitric oxide synthase during tumor promotion. Carcinogenesis 1996；17：2053-2059.
50.Deliconstantinos G, Villiotou V, Stravrides JC. Release by ultraviolet B（u.v. B）radiation of nitric oxide（NO）from human keratinocytes: a potential role for nitric oxide in erythemal production. Br J Pharmacol 1995；114：1257-1265.
51.Baudouin JE, Tachon P. J Invest Dermatol 1996；428-431.
52.Ahmad NA, Srivastava RC, Agarwal R, et al. Nitric oxide synthase and skin tumor promotion. Biochim Biophys Res Commu 1997；232：328-331.
53.Dong Z, Staroselsky AH, Qi X, et al. Inverse correlation between expression of inducible nitric oxide synthase activity and production of metastasis in K-1735 murin melanoma cells. Cancer Res 1994；54：789-793.
54.Rajnakova A, Goh PM, Chan ST, et al. Expression of differential nitric oxide synthase isoforms in human normal gastric mucosa and gastric cancer tissue. Carcinogenesis 1997；18：1941-1945.
55.Moochhala S, Chhatwal VJ, Chan SJ, et al. Nitric oxide synthase activity and expression in human colorectal cancer. Carcinogenesis 1996；17：1171-1174.
56.Thomsen LL, Lawton FG, Knowles RG, et al. Nitric oxide synthase activity in human gynecological cancer. Cancer Res 1994；54：1352-1354.
57.Forstermann U, Gorsky LD, Pollock JS, et al. Hormone-induced biosynthesis of endothelium-derived relaxing factor/nitric oxide-like material in NiE-115 neuroblastoma cells require calcium and camodulin. Mol Pharm 1990；38：7-13.
58.Amber IJ, Hibbs JB, Taintor RR, et al. The L-arginine dependent effector mechanism is induced in murine adenocarcinoma cells by culture supernatant from cytotoxic activated macrophages. J Leukoc Biol 1988；43：187-192.
59.Calderon C, Huang Z, Gage DA, et al. Isolation of nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. J Exp Med 1994；180：945-958.
60.Maragos CM, Wang JM, Hrabie JA, et al. Nitric oxide/nucleophil complexes inhibit the in vitro proliferation of A375 melanoma cells via nitric oxide release. Cancer Res 1993；53：564-568.
61.Culotta E, Koshland DE Jr. NO news is good news. Science 1992；258：1862-1865.
62.Morris AL. Factors influencing experimental carcinogenesis in the hamster cheek pouch. J Dent Res 1961；40：3-15.
63.Gimenez-Conti IB, Slaga TJ. The hamster cheek pouch carcinogenesis model. J Cell Biochem 1993；17F（Suppl）83-90.
64.Salley JJ. Experimental carcinogenesis in the cheek pouch of Syrian hamster. Dent Res 1954；33：253-262.
65.Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex ( ABC ) in immunoperoxidase techniques: a comparison between ABC and unlabelled antibody ( PAP ) procedures. J Histochem Cytochem 1981；29：577-580.
66.Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987；162：156-159.
67.Doi C, Noguchi Y, Marat D, et al. Expression of nitric oxide synthase in gastric cancer. Cancer Lett 1999；144：161-167.
68.Murakami A, Kawabata K, Koshiba T, et al. Nitric oxide synthase is induced in tumor promoter-sensitive, but not tumor promoter-resistant. JB6 mouse epidermal cells cocultured with interferon-γ-stimulated RAW 264.7 cells: The role of tumor necrosis factor-α. Cancer Res 2000；60：6326-6331.
69.Ohshima H, Bartsch H. Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994；305：253-264.
70.Tamir S, Tannenbaum SR. The role of nitric oxide（NO）in the carcinogenesis process. Biochem Biophys Acta. 1996；1288：F21-36.
71.Calmels S, Hainaut P, Ohshima H. Nitric oxide induces conformational and functional modifications of wild-type p53 tumor suppressor protein. Cancer Res 1997；57：3365-3369.
72.Fujimoto H, Sasaki JI, Matsumoto M, et al. Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma. Jpn J Cancer Res 1998；89：696-702.
73.Xie K, Huang S, Dong Z, et al. Transfection with inducible nitric oxide synthase gene suppresses tumorigenicity and abrogates metastasis in K-1735 murine melanoma cells. J Exp Med 1995；181：1333-1343.
74.Ambs S, Hussain SP, Harris CC. Interactive effects of nitric oxide and the p53 tumor suppresses gene in carcinogenesis and tumor progression FASEB J 1997；11：433-438.
75.Fukumura D, Jain RK. Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Meta Rev 1998；17：77-89.
76.Doi K, Akaike T, Horie H, et al. Excessive production of nitric oxide in rat solid tumor and it implication in rapid tumor growth. Cancer 1996；77：1598-1604.
77.Brennan PA, Conroy B, Sinclair D, Spedding AV. Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000；90：624-629.
78.Brennan PA, Palacios-Callender M, Sinclair D, Spedding AV, Zaki GA. Correlation between type II nitric oxide synthase and p53 expression in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2000；38：627-632.
79.Fu S, Ramanujam KS, Wong A, Fantry GT. Increased expression and cellular localization of iNOS and CSO-2 in Helicobacter pylori gastritis. Gastroenterology 1999；116：1319-1329.
80.Dijksta G, Moshage H, van Dullemen HM, et al. Expression of nitric oxide synthase and formation of nitrotryosine and reactive oxygen species in inflammatory bowel disease J. Pathol 1998；186：416-421.
81.Liu CY, Wang CH, Chen TC, Yu CT, Kuo HP. Increased level of exhaled nitric oxide and up-regulation of nitric oxide synthase in patients with primary lung cancer. Br J Cancer 1998；78：534-541.
82.Wilson KT, Fu S, Ramanujam KS, Meltzer SJ. Increased expression of iNOS and COX-2 in the Barrett’s esophagus an associated adenocarcinomas. Cancer Res 1998；58：2929-2934.
83.Klotz T, Bloch W, Volberg C, Engelmann U, Addicks K. Selective expression of inducible nitric oxide synthase in human prostate carcinoma. Cancer 1998；82：1897-1903.
84.Brennan PA. Palacios-Callender M, Sinclair D, Spedding AV, Zaki GA. Dose expression of inducible nitric oxide synthase correlate with severity of oral epithelial dysplasia？ J Cranto-Maxillofac Surg 2000；28：44-48.
85.Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD. Type II nitric oxide synthase（NOS2）expression correlates with lymph node status in squamous cell carcinoma. J Oral Pathol Med 2001；30：129-134.
86.Chen YK, Lin LM. Immunohistochemical expression of inducible nitric oxide synthase in DMBA-induced hamster buccal pouch carcinogenesis. Oral Oncol 2000；36：221-214.
87.Rosbe KW, Prazma J, Petrusz P, Mims W, Ball SS, Weissler MC. Immunohistochemical characterization of nitric oxide synthase activity in squamous cell carcinoma of head and neck. Otolaryngo Head Neck Surg 1995；113：541-549.
88.Brennan PA, Palacios-Callender M, Sinclair D, Spedding AV, Zaki GA. Correlation between type II nitric oxide synthase and p53 expression in oral squamous cell carcinoma. Br J Oral Maxillofac Surg 2000；38：627-632.
89.Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD. Type II nitric oxide synthase （NOS2）expression correlates with lymph node status in squamous cell carcinoma. J Oral Pathol Med 2001；30：129-134.
90.Doi C, Noguchi Y, Marat D, Saito A, Fukuzawa K, Yoshikawa T, Tsuburaya A, Ito T. Expression of nitric oxide synthase in gastric cancer. Cancer Lett 1999；144：161-167.
91.D’Ambrosio SM, Gibson-D’Ambrosio RT, Brady T, Oberyszyn AS, Roberston FM. Mechanisms of nitric oxide-induced cytotoxicity in normal human hepatocytes. Environ Mol Mutagen 2001；27：46-54.
92.Brennan PA, Palacios-Callender M, Zaki GA, Spedding AV, Langdon JD. Type II nitric oxide synthase （NOS2）expression correlates with lymph node status in squamous cell carcinoma. J Oral Pathol Med 2001；30：129-134.
93.Brennan PA, Conroy B, Sinclair D, Spedding AV. Expression of inducible nitric oxide synthase and p53 in oral epithelial dysplasia. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000；90：624-629.
94.Brennan PA, Palacios-Callender M, Sinclair D, Spedding AV, Zaki GA. Does expression of inducible nitric oxide synthase correlate with severity of oral epithelial dysplasia? J Cranio-Maxillofac Surg 2000；28：44-48.
95.Xiao-Jing Zhang., Jane H. Thompson, Elizabeth E. Mannick, Pelayo Correa, and Mark J. S. Miller. Loaclization of inducible nitric oxide synthase mRNA in inflamed gastrointestinal mucosa by in situ reverse transcriptase-polymerase chain reaction. Nitric Oxide: Biology and Chemsitry. 1998; 2, 187-192.
96.Messmer U.K. & Brune B. Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. Biochem. J. 1996; 319, 299-305.
97.Forrester K. et al. Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase ( NOS2 ) expression by wild-type p53. Proc. Natl. Acad. Sci. USA 1996; 93, 2442-2447.
98.Polyak K., Waldman T., He T.C., Kinzler K.W. & Vogeistein B. Genetic determinants of p53-induced apoptosis and growth arrest. Genes Dev. 1996; 1945-1952..
99.Dameron K.M., Volpert O.V., Tainsky M.A., Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994; 265, 1582-1584.
100. Stefan Ambs., William G. p53 and vascular endothelial growth factor regulate tumor growth of NOS2-expressing human carcinoma cells. Nature Medicine 1998; 4, 1371-1376.